Skip to content
Sign in
Moderna and Merck’s personalized mRNA cancer vaccine shows significant efficacy in melanoma trialAI illustration
DevelopingHealthPolicyScienceReported 2026-10-23 03:03

Moderna and Merck’s personalized mRNA cancer vaccine shows significant efficacy in melanoma trial

A personalized mRNA cancer vaccine from Moderna and Merck reduced the risk of disease recurrence in melanoma patients by 42%, according to a large clinical trial. The vaccine, intismeran autogene, targets unique tumor mutations and could lead to new cancer treatments.

In depthRead the in-depth story

Why it matters. Oncologists and cancer patients may benefit from a new wave of personalized cancer therapies that could improve survival rates and treatment options.

01

Evidence

  • SSTATMedia2026-10-23 03:03
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 10:15
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 10:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 11:00
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 10:45
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 11:15
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 11:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 11:45
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 12:00
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 12:15
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 12:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 13:15
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 13:00
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 13:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 14:00
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 13:45
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 14:15
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-24 14:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-23 16:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-23 17:45
    View source